Myriad Genetics Reports Q3 2026 Results and Announces Prenatal Health Divestiture to Labcorp
Myriad Genetics (MYGN) reported third-quarter 2026 revenue of $202.7 million, driven by growth in its Cancer Care and Mental Health segments despite a significant 12% decline in Prenatal Health revenue. While the company posted a non-GAAP EPS loss of $0.11, management noted sequential improvements in laboratory efficiency and adjusted gross margins, which rose to 67.9%. A major strategic shift was announced via the all-cash sale of its Prenatal Health business to Labcorp for $210 million plus inventory. This divestiture is expected to significantly improve Myriad's financial profile by expanding gross margins by over 500 basis points and accelerating revenue growth post-transaction. Following these results, the company raised its full-year 2026 revenue guidance to a range of $780 million to $790 million.
Topics: Cancer Care Divestiture EBITDA EPS Mental Health Revenue
Read the full article at Motley Fool
Part of the story Myriad Genetics Reports Q3 2026 Results and Announces Prenatal Health Divestiture to Labcorp (4 articles)